You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChloroprocaine
Accession NumberDB01161  (APRD00404)
TypeSmall Molecule
GroupsApproved
DescriptionChloroprocaine hydrochloride is a local anesthetic given by injection during surgical procedures and labor and delivery. Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential.
Structure
Thumb
Synonyms
2-Chloroprocaine
4-amino-2-Chlorobenzoic acid 2-(diethylamino)ethyl ester
Chloroprocain
Chloroprocaine
Chloroprocainum
Chlorprocaine
Cloroprocaina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nesacaineinjection, solution20 mg/mLinfiltration; perineuralGeneral Injectables & Vaccines, Inc2013-01-30Not applicableUs
Nesacaineinjection, solution10 mg/mLinfiltration; perineuralGeneral Injectables & Vaccines, Inc2011-10-03Not applicableUs
Nesacaineinjection, solution10 mg/mLinfiltration; perineuralFresenius Kabi USA, LLC2010-10-14Not applicableUs
Nesacaineinjection, solution20 mg/mLinfiltration; perineuralFresenius Kabi USA, LLC2010-10-14Not applicableUs
Nesacaine Ce 2% Inj 20mg/mlsolution20 mgintracaudal; epiduralAstrazeneca Canada Inc1984-12-312012-05-31Canada
Nesacaine Ce 3% Inj 30mg/mlsolution30 mgintracaudal; epiduralAstrazeneca Canada Inc1984-12-312005-08-02Canada
Nesacaine Mpfinjection, solution30 mg/mLepidural; infiltration; intracaudal; perineuralFresenius Kabi USA, LLC2010-10-14Not applicableUs
Nesacaine Mpfinjection, solution20 mg/mLepidural; infiltration; intracaudal; perineuralFresenius Kabi USA, LLC2010-10-14Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chloroprocaine Hydrochlorideinjection, solution20 mg/mLepidural; infiltrationHospira, Inc.1982-04-16Not applicableUs
Chloroprocaine Hydrochlorideinjection, solution30 mg/mLepidural; infiltrationHospira, Inc.1982-04-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Nesacaine-CEAstraZeneca
PiocaineNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Chloroprocaine hydrochloride
Thumb
  • InChI Key: SZKQYDBPUCZLRX-UHFFFAOYSA-N
  • Monoisotopic Mass: 306.090183308
  • Average Mass: 307.216
DBSALT000823
Categories
UNII5YVB0POT2H
CAS number133-16-4
WeightAverage: 270.755
Monoisotopic: 270.113505569
Chemical FormulaC13H19ClN2O2
InChI KeyInChIKey=VDANGULDQQJODZ-UHFFFAOYSA-N
InChI
InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 4-amino-2-chlorobenzoate
SMILES
CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentBenzoic acid esters
Alternative Parents
Substituents
  • Halobenzoic acid or derivatives
  • 2-halobenzoic acid or derivatives
  • Benzoate ester
  • Aminobenzoic acid or derivatives
  • Benzylether
  • Substituted aniline
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Primary aromatic amine
  • Aryl halide
  • Aryl chloride
  • Vinylogous halide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia.
PharmacodynamicsChloroprocaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Chloroprocaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Chloroprocaine is an ester anesthetic.
Mechanism of actionChloroprocaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. It is hypothesized that Chloroprocaine binds or antagonizes the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
Related Articles
AbsorptionThe rate of systemic absorption of local anesthetic drugs is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic injection.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase.

Route of eliminationChloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH.
Half life21 +/- 2 seconds
ClearanceNot Available
ToxicityIn mice, the intravenous LD50 of chloroprocaine HCl is 97 mg/kg and the subcutaneous LD50 of chloroprocaine HCl is 950 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Chloroprocaine Action PathwayDrug actionSMP00394
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.954
Caco-2 permeable+0.6107
P-glycoprotein substrateSubstrate0.5855
P-glycoprotein inhibitor INon-inhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.9707
Renal organic cation transporterNon-inhibitor0.6843
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateNon-substrate0.6718
CYP450 3A4 substrateNon-substrate0.5215
CYP450 1A2 substrateInhibitor0.7507
CYP450 2C9 inhibitorNon-inhibitor0.8687
CYP450 2D6 inhibitorInhibitor0.7746
CYP450 2C19 inhibitorNon-inhibitor0.8061
CYP450 3A4 inhibitorNon-inhibitor0.8334
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6017
Ames testNon AMES toxic0.6613
CarcinogenicityNon-carcinogens0.6653
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.7123 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8353
hERG inhibition (predictor II)Inhibitor0.5819
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionepidural; infiltration20 mg/mL
Injection, solutionepidural; infiltration30 mg/mL
Injection, solutioninfiltration; perineural10 mg/mL
Injection, solutioninfiltration; perineural20 mg/mL
Solutionintracaudal; epidural20 mg
Solutionintracaudal; epidural30 mg
Injection, solutionepidural; infiltration; intracaudal; perineural20 mg/mL
Injection, solutionepidural; infiltration; intracaudal; perineural30 mg/mL
Prices
Unit descriptionCostUnit
Nesacaine-mpf 3% vial1.34USD ml
Nesacaine-mpf 2% vial1.28USD ml
Nesacaine 2% vial0.74USD ml
Nesacaine 1% vial0.72USD ml
Chloroprocaine 3% vial0.33USD ml
Chloroprocaine 2% vial0.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point173-174Marks, H.C. and Rubin, M.I.; US. Patent 2,460,139; January 25,1949; assigned to Wallace & Tiernan Products, Inc.
water solubility0.665 mg/mLNot Available
logP2.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.3 mg/mLALOGPS
logP2.72ALOGPS
logP2.48ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.56 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity75.1 m3·mol-1ChemAxon
Polarizability28.74 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-9100000000-5a6841e384b0dfbd1238View in MoNA
References
Synthesis Reference

Marks, H.C. and Rubin, M.I.; US. Patent 2,460,139; January 25,1949; assigned to Wallace
& Tiernan Products, Inc.

General ReferencesNot Available
External Links
ATC CodesN01BA04
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (182 KB)
MSDSDownload (51.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chloroprocaine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chloroprocaine.
AmisulprideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Azaperone.
AzelastineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chloroprocaine.
BaclofenThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chloroprocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
BrimonidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloroprocaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chloroprocaine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloroprocaine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chloroprocaine.
ButacaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chloroprocaine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloroprocaine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chloroprocaine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlormezanone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloroprocaine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloroprocaine.
CitalopramThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloroprocaine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Chloroprocaine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chloroprocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chloroprocaine.
CyclizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.
CyproheptadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloroprocaine.
DapoxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloroprocaine.
DextromoramideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloroprocaine.
DezocineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chloroprocaine.
DifenoxinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloroprocaine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloroprocaine.
DoramectinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
DoxylamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Chloroprocaine.
DrotebanolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.
EcgonineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chloroprocaine.
EntacaponeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloroprocaine.
EthanolChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Chloroprocaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloroprocaine.
EthosuximideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloroprocaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloroprocaine.
FexofenadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloroprocaine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloroprocaine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chloroprocaine.
FluspirileneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chloroprocaine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chloroprocaine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloroprocaine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chloroprocaine.
HeroinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Chloroprocaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chloroprocaine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chloroprocaine.
KetamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chloroprocaine.
LevocabastineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chloroprocaine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chloroprocaine.
LithiumThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chloroprocaine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chloroprocaine.
Lu AA21004The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chloroprocaine.
MelperoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloroprocaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloroprocaine.
MetaxaloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chloroprocaine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chloroprocaine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloroprocaine.
MethsuximideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloroprocaine.
MetyrosineChloroprocaine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine.
MilnacipranThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
MirtazapineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chloroprocaine.
MolindoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chloroprocaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.
NabiloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloroprocaine.
NitrazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chloroprocaine.
OpiumThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Opium.
OrphenadrineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chloroprocaine.
OsanetantThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chloroprocaine.
OxprenololThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chloroprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloroprocaine.
OxymorphoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paliperidone.
ParaldehydeChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Chloroprocaine.
ParoxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloroprocaine.
PerampanelThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chloroprocaine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chloroprocaine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chloroprocaine.
PipamperoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pomalidomide.
PramipexoleChloroprocaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chloroprocaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chloroprocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chloroprocaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloroprocaine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Chloroprocaine.
PromethazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chloroprocaine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chloroprocaine.
PropoxycaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Chloroprocaine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloroprocaine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chloroprocaine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloroprocaine.
RomifidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Romifidine.
RopiniroleChloroprocaine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloroprocaine.
RotigotineChloroprocaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chloroprocaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloroprocaine.
SertindoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloroprocaine.
SuvorexantThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptChloroprocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chloroprocaine.
TetrabenazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrodotoxin.
ThalidomideChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chloroprocaine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloroprocaine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chloroprocaine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chloroprocaine.
ThiothixeneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloroprocaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroprocaine.
TrazodoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chloroprocaine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloroprocaine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloroprocaine.
TrimipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chloroprocaine.
VigabatrinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chloroprocaine.
ZiconotideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine.
ZolazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chloroprocaine.
ZonisamideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wong K, Strichartz GR, Raymond SA: On the mechanisms of potentiation of local anesthetics by bicarbonate buffer: drug structure-activity studies on isolated peripheral nerve. Anesth Analg. 1993 Jan;76(1):131-43. [PubMed:8418714 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Wilcox KM, Paul IA, Ordway GA, Woolverton WL: Role of the dopamine transporter and the sodium channel in the cocaine-like discriminative stimulus effects of local anesthetics in rats. Psychopharmacology (Berl). 2001 Sep;157(3):260-8. [PubMed:11605081 ]
  2. Mansbach RS, Jortani SA, Balster RL: Discriminative stimulus effects of esteratic local anesthetics in squirrel monkeys. Eur J Pharmacol. 1995 Feb 14;274(1-3):167-73. [PubMed:7768269 ]
  3. Wilcox KM, Paul IA, Woolverton WL: Comparison between dopamine transporter affinity and self-administration potency of local anesthetics in rhesus monkeys. Eur J Pharmacol. 1999 Feb 19;367(2-3):175-81. [PubMed:10078990 ]
  4. Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL: On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology (Berl). 2000 Dec;153(1):139-47. [PubMed:11255924 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kuhnert BR, Philipson EH, Pimental R, Kuhnert PM: A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase. Anesthesiology. 1982 Jun;56(6):477-8. [PubMed:7081736 ]
  2. Tucker GT, Mather LE: Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet. 1979 Jul-Aug;4(4):241-78. [PubMed:385208 ]
  3. Monedero P, Hess P: High epidural block with chloroprocaine in a parturient with low pseudocholinesterase activity. Can J Anaesth. 2001 Mar;48(3):318-9. [PubMed:11305839 ]
  4. Smith AR, Hur D, Resano F: Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency. Anesth Analg. 1987 Jul;66(7):677-8. [PubMed:3111302 ]
  5. Raj PP, Ohlweiler D, Hitt BA, Denson DD: Kinetics of local anesthetic esters and the effects of adjuvant drugs on 2-chloroprocaine hydrolysis. Anesthesiology. 1980 Oct;53(4):307-14. [PubMed:7425357 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23